Highest-materiality recent filing
Silexion receives Nasdaq delisting notice for equity shortfall; plans appeal
Nasdaq delisting notice received Aug 18, 2026 for failure to meet $2.5M shareholders' equity requirement (Rule 5550(b)(1)).
Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated
Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.
Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern
FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.
Silexion closes $2.5M public offering; converts $750K debt to equity
Offered 2,028,619 shares, 1,817,542 pre-funded warrants, 3,846,161 Series E warrants at $0.65/unit; gross proceeds ~$2.5M.
Silexion starts SIL204 Phase 2/3 in pancreatic cancer; FDA pre-IND expected Q1 2027
Phase 2/3 safety run-in for SIL204 in LAPC initiated July 2026; approved by Israel MoH and Germany BfArM.
Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers
SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.
Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation
Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.
Director Amnon Peled resigns from Silexion Therapeutics board effective August 1, 2026
Professor Amnon Peled resigned from the Board of Directors for personal reasons, effective August 1, 2026.
First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.
Silexion shareholders approve 10M share authorized increase and warrant exercisability
Meeting reconvened July 20, 2026 after July 13 adjournment due to lack of quorum.
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
1-for-10 reverse share split effective after close May 28; shares trade on split-adjusted basis May 29 under ticker SLXN.
Silexion Therapeutics announces 1-for-10 reverse share split to maintain Nasdaq listing
Reverse share split at 1:10 ratio; effective after market close May 28, 2026; split-adjusted trading begins May 29, 2026.
Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026
Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.
Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.
SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).
Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site
Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split
Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.
Silexion submitted CTA to Germany’s BfArM for Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer.
Silexion Therapeutics removes director Ilan Levin effective March 25, 2026
Ilan Levin removed from Board on March 25, 2026 by unanimous vote of other directors.
Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer
SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.
Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion
At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).
Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow
Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.
Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026
SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.
Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer
Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).
Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer
BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.
Silexion completes toxicology studies for SIL204; Phase 2/3 trial on track for Q2 2026
Two-species toxicology studies for SIL204 confirm no systemic organ toxicity, clearing path to regulatory filings.
Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026
Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.
SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.
Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright
At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.
Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor
Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.
Silexion regains Nasdaq compliance with $9.4M equity after capital raise
Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
Silexion Therapeutics prices $6.0M public offering of shares and warrants
Raised $6.0M gross ($5.2M net) from sale of 1.5M share equivalents and warrants at $4.00/unit.
Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model
Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.
Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected
CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.
Silexion posts updated corporate presentation for H.C. Wainwright conference
Updated corporate presentation posted to company website on September 2, 2025.
Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt
Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.
Silexion Therapeutics shareholders approve 6x increase in authorized shares to 9M
Authorized capital raised from US$20,000 (1,481,482 shares) to US$121,500 (9,000,000 shares).
Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers
Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.
Silexion exercises 152K warrants at $11.57 for ~$1.8M gross; issues new warrants
Exercises 152,106 existing warrants at $11.57/share; gross proceeds ~$1.8M before fees.
SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).
Silexion Therapeutics effects 1-for-15 reverse stock split, adjusts warrant terms
Reverse split effective after close July 28; trading on split-adjusted basis July 29 under same ticker SLXN.
Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29
On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
Silexion Therapeutics announces 1-for-15 reverse share split to maintain Nasdaq listing
Reverse split effective after market close July 28; split-adjusted trading starts July 29 under ticker SLXN.
Silexion shareholders approve 1-for-15 reverse split and board election
Reverse share split at 1-for-15 ratio approved with 59.6% of votes in favor.
SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study
Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.
Nasdaq transfer to Capital Market not on July 8 as originally reported; now expected as soon as practicable.
Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.
Silexion Therapeutics appeals Nasdaq delisting; hearing set for June 26, 2025
Received Nasdaq delisting notice on May 22 for MVLS <$50M and MVPHS <$15M deficiencies.
Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic
SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.
Silexion Therapeutics receives Nasdaq delisting notice; plans appeal
Received delisting notice on May 22, 2025 for MVLS <$50M and MVPHS <$15M non-compliance.
On July 30, 2026, Professor Amnon Peled notified the Board of Directors (the “ Board ”) of Silexion Therapeutics Corp (the “ Company ”) of his resignation from his position as a member of the Board, for personal reasons, effective as of August 1, 2026.
On September 16, 2024, Ilan Shiloah, an independent director serving on the board of directors (the “Board”) of Silexion Therapeutics Corp, a Cayman Islands exempted company (the “Company”), informed the Company that he has resigned from the Board, including from his membership on each of the committees of the Board— the audit committee, the compensation committee, and the corporate governance and nominating committee— effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material